Insurance Denials Delay Critical Allergy Meds
Nearly 4 in 10 prescriptions for biologic medications used to treat children with allergic and atopic conditions were denied by insurers, and obtaining approval took an average of nearly 33 days, according to a new study presented at the American College of Allergy, Asthma, and Immunology (ACAAI) 2026 Annual Meeting . The findings highlight how prior authorization requirements can delay access to treatments for children with poorly controlled asthma , atopic dermatitis (AD), chronic urticaria , and immunoglobulin E-mediated food allergy. Researchers at the University of Missouri-Kansas City conducted a retrospective chart review of 326 biologic prescriptions written by allergists at a tertiary care pediatric center between 2018 and 2026. The median patient age was 11.4 years, and 50.3% of the patients were male. Overall, 93.6% of prescriptions required prior authorization, and 39.3% of those requests were denied. The mean time from prescription to insurance approval was 32.65 days, the study found. The most common reasons for denial were failure to meet insurers’ coverage criteria (24.4%) and requirements to try another medication first (23.4%). Omalizumab accounted for 55.8% of prescriptions, followed by dupilumab (26%). Other biologics evaluated included mepolizumab , benralizumab , and tezepelumab . Although most prescriptions were eventually approved, some took considerably longer, with delays exceeding 60 days, said study co-author Aarti Pandya, MD , medical director of the Food Allergy Center at Children’s Mercy in Kansas City, Missouri. Those delays can have important clinical consequences, particularly for children with asthma, AD, and food allergy, she said. “Atopic conditions can have serious and life-threatening complications such as asthma exacerbations, secondary infections from uncontrolled atopic dermatitis, anaphylaxis from food allergy accidental exposure,” Pandya said. Payel Gupta, MD, allergist-immunologist in Brooklyn, New York, and member of the Allergy & Asthma Network’s Medical Advisory Council, was not involved in the study and said delays can be particularly dangerous for children with moderate-to-severe asthma who need biologics to control airway inflammation. If a child is exposed to an allergen or develops a respiratory infection while waiting for treatment, additional airway inflammation could lead to hospitalization, she said. “These delays really impact patient care and, like I said, they can be catastrophic at times,” Gupta said. Biologics target specific components of the immune system involved in allergic and inflammatory diseases. They are generally used when conventional therapies have not adequately controlled symptoms and may be administered by injection. Access to biologic medications for allergies has been shown to reduce the risk for serious complications. One challenge is that insurance plans establish their own coverage criteria rather than consistently following guideline-based recommendations, Pandya said. This creates opportunities for delays across biologic medications and indications. Pandya called for standardizing prior authorization requirements, improving transparency, and making the process easier for clinicians to navigate. Gupta pointed to several potential policy solutions, including the proposed Safe Step Act , which would establish a clearer, faster exception process for patients who need medications without first completing insurer-mandated treatment steps. Another approach would be to expand “gold carding,” which exempts physicians with consistently high prior authorization approval rates from submitting requests for certain prescriptions, Gupta said. “Then [the physician] wouldn’t have to do prior authorizations for prescriptions because it’s already been established that they know what they’re doing,” Gupta said. Gupta also called for insurers to honor existing treatment approvals when patients switch health plans rather than requiring families and clinicians to restart the authorization process. Pandya agreed that practical changes, including standardized authorization criteria and templates, faster communication from insurers, and tools integrated into electronic health records, could help streamline the process for clinicians. “The [prior authorization] process must be standardized, with better transparency and ease of completion for clinicians,” she said. Pandya and Gupta reported no relevant disclosures. Lara Salahi is a health journalist based in Boston.